Effect of "Aminopterin" on Epithelial Tissues

Gubner, Richard

doi:10.1001/archderm.1951.01570120023004

Cited by 109 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of folic acid antagonists in rheumatoid arthritis and psoriasis was introduced by Gubner 168 ,169 in 1951. Six of 7 patients with rheumatoid arthritis had transient increase in mobility and decrease in pain for periods lasting up to 6 weeks at dose levels of 4-aminofolic acid which caused intoxication.…”

Section: Folic Acid Antagonists and Psoriasismentioning

confidence: 99%

“…It is of interest that all three dermato-logiC investigators cited above were unable to produce regression of psoriatic lesions by local application of 1 per cent 4-aminofolic acid ointment to 4 patients, 169 1 per cent 4-aminofolic acid ointment to 12 pa-tientsl7l or amethopterin as a powder or in acid or alkaline solution, even after removal of the stratum corneum by cellulose tape. 71 In the latter instance, some transdermal absorption was proved by the finding of amethopterin in the urine.…”

Section: Folic Acid Antagonists and Psoriasismentioning

confidence: 99%

See 1 more Smart Citation

Part VIII. Folic acid antagonists

Holland

1961

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Section: Folic Acid Antagonists and Psoriasismentioning

confidence: 99%

Section: Folic Acid Antagonists and Psoriasismentioning

confidence: 99%

Part VIII. Folic acid antagonists

Holland

1961

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

“…Since its introduction by Farber, Diamond & Mercer (1948) methotrexate has been established in the chemotherapy of several malignant diseases (Capizzi, de Conti, Marsh & Bertino, 1970;Mitchell, Wawro, de Corti, Kaplan, Papac & Butino, 1968;Gottlieg & Serpick, 1970;Jaffe, 1972;Chabner, Myers, Coleman & Johns, 1975; Vincent, Pickren, Fergus & Takita, 1975). Gubner (1951) first described the effect of methotrexate on epithelial tissue and the drug has subsequently been used to treat some cases of psoriasis (McDonald & Bartino, 1969;Spiro & Dermis, 1969;Van Scott, Auerbach & Weinstein, 1964;Weistein, 1971;Baker, 1970).…”

Section: Introductionmentioning

confidence: 99%

Serum, tear and salivary concentrations of methotrexate in man.

Steele¹,

Stuart²,

Whiting³

et al. 1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Methotrexate handling has been studied in four patients with psoriasis and eleven patients with neoplastic disease. 2. Methotrexate levels in serum, tears and saliva were measured by radioimmunoassay while protein binding studies were performed by continuous ultrafiltration. 3. There was a close correlation between methotrexate concentrations in tears and serum (P less than 0.001, r = 0.714). Parotid salivary and serum methotrexate levels were similarly correlated (P less than 0.001, r = 0.557) but not mixed salivary and serum levels (P greater than 0.1, r = 0.232). 4. The mean protein binding was 95.11% +/‐ 2.26 (s.d.) while the ratio of methotrexate levels in tears to the free serum methotrexate level was 1:1.04. The corresponding parotid salivary level: free serum level ratio was 1:18.11. 5. No relationship could be determined between the methotrexate levels in tears and conjunctivitis observed in some of the patients under study.

show abstract

“…had a remission at New York's Kings County Hospital with aminopterin conceived and developed by Yellapragada SubbaRow as an anti-cancer drug. [2][3][4] Because of ambivalent reports about aminopterin's toxicity, this might have found a footnote in medical history but for the switch from aminopterin to its relatively less toxic analog methotrexate made by Edmundson and Guy of Pittsburgh. 5 Most dermatologists are, however, unaware of this significant role by India-born SubbaRow (Su as in supine and Row as in tao) in the introduction of methotrexate, also developed in his laboratory, for the treatment of psoriasis.…”

mentioning

confidence: 99%